Vitrolife AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
February 02, 2024 at 02:00 am
Share
Vitrolife AB (publ) reported earnings results for the fourth quarter and full year ended December 31, 2023. For the fourth quarter, the company reported sales was SEK 904 million compared to SEK 855 million a year ago. Net loss was SEK 4,179 million compared to net income of SEK 74 million a year ago. Basic loss per share from continuing operations was SEK 30.86 compared to basic earnings per share from continuing operations of SEK 0.55 a year ago.
For the full year, sales was SEK 3,512 million compared to SEK 3,234 million a year ago. Net loss was SEK 3,851 million compared to net income of SEK 394 million a year ago. Basic loss per share from continuing operations was SEK 28.44 compared to basic earnings per share from continuing operations of SEK 2.91 a year ago.
Vitrolife AB is a Sweden-based company engaged in assisted reproduction services. The Companyâs product portfolio comprises G-RINSE, which is a solution for rinsing of contact materials, EmbryoGlue, which is a human albumin recombinant, ASP, which is a solution for oocyte retrieval and rinsing, and Semen VTS, which is a viscosity treatment system, among others. It also provides a range of procedural solutions for sperm preparation, vitrification, embryo transfer and oocyte retrieval, such as temperature control, condition control, gamete-safe labware and embryo support. The Company is active in Australia, China, France, Italy, Japan, the United States and the United Kingdom, among others, and conducts its business through a number of subsidiaries, such as Vitrolife Ltd., Vitrolife Pty Ltd., and A.T.S. Srl.
VITROLIFE AB 
